Skip to main content
SpringerLink
Log in

Biological meaning of stage and grade in human breast cancer: Review and hypothesis

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Because of the high probability that breast cancer patients have experienced systemic dissemination prior to their initial treatment, the determination of tumor stage and grade should not be considered an estimate of the likelihood of eventual metastasis. An examination of staging and grading parameters reveals strong associations among measures of tumor stage, and a relative independence of those measures from tumor grade. Similarly, measures of tumor grade tend to be expressed at approximately the same level in the individual patient, but are relatively independent of tumor stage. In clinical human breast cancer, tumor ‘stage’ would appear to be an estimate of body burden of tumor, and tumor ‘grade’ an estimate of growth rate. Together they provide, with some degree of probability, an estimate of the amount of time between initial presentation and recurrence. In order to increase the probability with which this estimate can be made, greater precision is needed in our determinations of prognostic indices, particularly those of tumor grade. Biochemical measurement of estrogen receptors and other biological products, and tumor morphometry, may help to alleviate this problem. Patient prognosis can best be evaluated by combining estimates of tumor stage and grade, rather than relying upon only one.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meissner WA, Diamandopoulos GT: Neoplasia.In WAD Anderson and JM Kissane (eds). Pathology, 7th edition. CV Mosby Co, St Louis, 1977, pp 640–683.

    Google Scholar 

  2. Sugarbaker PH, Dunnick NR, Sugarbaker EV: Diagnosis and staging.In VT Devita Jr, S Hellman, and SA Rosenberg (eds). Cancer: Principles and Practice of Oncology. JB Lippincott, Philadelphia, 1982, pp 226–261.

    Google Scholar 

  3. Fisher B: Laboratory and clinical research in breast cancer — a personal adventure. Cancer Res 40: 3863–3874, 1980.

    Google Scholar 

  4. Haagensen CD: Diseases of the Breast, 2nd edition (revised). WB Saunders, Philadelphia, 1971.

    Google Scholar 

  5. Fisher B, Slack NH, Bross IDJ, and Cooperating Investigators: Cancer of the breast: Size of the neoplasm and prognosis. Cancer 24: 1071–1080, 1969.

    Google Scholar 

  6. Cutler SJ, Meyers MH, Green SB: Trends in survival rates of patients with cancer. N Engl J Med 293: 122–124, 1975.

    Google Scholar 

  7. Shackney SE, McCormack GW, Cuchural GJ Jr: Growth rate patterns of solid tumors and their relation to responsiveness to therapy: An analytical review. Ann Intern Med 89: 107–121, 1978.

    Google Scholar 

  8. Philippe E, Le Gal Y: Growth of 78 recurrent mammary cancers: A quantitative study. Cancer 21: 461–467, 1978.

    Google Scholar 

  9. Pearlman AW: Breast cancer — influence of growth rate on prognosis and treatment evaluation: A study based on mastectomy scar recurrences. Cancer 38: 1826–1833, 1976.

    Google Scholar 

  10. Collins VP, Loeffler RK, Tivey H: Observations on growth rates of human tumors. Am J Roentgenol 76: 988–1000, 1956.

    Google Scholar 

  11. Gullino PM: Natural history of breast cancer: Progression from hyperplasia to neoplasia as predicted by angiogenesis. Cancer 39: 2697–2703, 1977.

    Google Scholar 

  12. Weiss L: A pathobiologic overview of metastasis. Semin Oncol 4: 5–17, 1977.

    Google Scholar 

  13. Weiss L: Dynamic aspects of cancer cell populations in metastasis. Am J Pathol 97: 601–608, 1979.

    Google Scholar 

  14. Bauer WC, Le Gal Y: An estimation of the size of breast carcinoma at time of first lymph node metastasis (Abstract). Lab Invest 28: 377–378, 1973.

    Google Scholar 

  15. Bloom HJG, Richardson W, Harries EJ: Natural history of untreated breast cancer (1805–1933): Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J 2: 213–221, 1962.

    Google Scholar 

  16. Adair F, Berg J, Joubert L, Robbins GF: Long-term followup of breast cancer patients: The 30-year report. Cancer 33: 1145–1150, 1974.

    Google Scholar 

  17. Brinkley D, Haybittle JL: The curability of breast cancer. Lancet 2: 95–97, 1975.

    Google Scholar 

  18. Mueller CB, Ames F, Anderson GD: Breast cancer in 3,558 women: Age as a significant determinant in the rate of dying and causes of death. Surgery 83: 123–132, 1978.

    Google Scholar 

  19. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR: Causes of death in breast cancer: A clinicopathologic study. Cancer 46: 162–167, 1980.

    Google Scholar 

  20. Charlson ME, Feinstein AR: An analytic critique of existing systems of staging for breast cancer. Surgery 73: 579–598, 1973.

    Google Scholar 

  21. Silverberg SG: Staging in the therapy of cancer of the breast. Am J Clin Pathol 64: 756–763, 1975.

    Google Scholar 

  22. Wallace IWJ, Champion HR: Axillary nodes in breast cancer. Lancet 1: 217–218, 1972.

    Google Scholar 

  23. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC, and Cooperating Investigators: The pathology of invasive breast cancer: A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol no. 4). Cancer 36: 1–85, 1975.

    Google Scholar 

  24. Fisher ER, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4): VI. Discriminants for five-year treatment failure. Cancer 46: 908–918, 1980.

    Google Scholar 

  25. Cutler SJ, Myers MH: Clinical classification of extent of disease in cancer of the breast. JNCI 39: 193–207, 1967.

    Google Scholar 

  26. Duncan W, Kerr GR: The curability of breast cancer. Br Med J 2: 781–783, 1976.

    Google Scholar 

  27. Langlands AO, Kerr GR: Prognosis in breast cancer: The relevance of clinical staging. Clin Radiol 2: 599–606, 1978.

    Google Scholar 

  28. Bloom HJG: The influence of delay on the natural history and prognosis of breast cancer. Br J Cancer 19: 228–262, 1965.

    Google Scholar 

  29. Fisher ER, Redmond C, Fisher B: A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer 40: 3160–3167, 1977.

    Google Scholar 

  30. Carter D, Smith RRL: Carcinoma in situ of the breast. Cancer 40: 1189–1193, 1977.

    Google Scholar 

  31. Rosen PP, Senie R, Schottenfeld D, Ashikari R: Noninvasive breast carcinoma: Frequency of unsuspected invasion and implications for treatment. Ann Surg 189: 377–382, 1979.

    Google Scholar 

  32. Ashikari R, Hajdu SI, Robbins GF: Intraductal carcinoma of the breast. Cancer 28: 1182–1187, 1971.

    Google Scholar 

  33. Rosen PP, Braun DW, Kinne DE: The clinical significance of pre-invasive breast carcinoma. Cancer 46: 919–925, 1980.

    Google Scholar 

  34. Ozzello L: Ultrastructure of intra-epithelial carcinomas of the breast. Cancer 8: 1508–1515, 1971.

    Google Scholar 

  35. Andersen JA, Fechner RE, Lattes R, Rosen PP, Toker C: Lobular carcinoma in situ (lobular neoplasia) of the breast (A symposium).In SC Sommers and PP Rosen (eds). Pathology Annual: 1980, Part I. Appleton-Century Crofts, New York, 1980, pp. 193–223.

    Google Scholar 

  36. Betsill WL, Rosen PP, Lieberman PH, Robbins GF: Intraductal carcinoma: Long-term follow-up after treatment by biopsy alone. JAMA 239: 1863–1867, 1978.

    Google Scholar 

  37. Page DL, Dupont WD, Rogers LW, Landenberger M: Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 49: 751–758, 1982.

    Google Scholar 

  38. Gallager HS, Martin JE: An orientation to the concept of minimal breast cancer. Cancer 28: 1505–1507, 1971.

    Google Scholar 

  39. Hutter RVP: The pathologist's role in minimal breast cancer. Cancer 28: 1527–1536, 1971.

    Google Scholar 

  40. Smart CR, Myers MH, Gloeckler LA: Implications fromSeer data on breast cancer management. Cancer 41: 787–789, 1978.

    Google Scholar 

  41. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45: 2917–2924, 1980.

    Google Scholar 

  42. Bedwani R, Vana J, Rosner D, Schmitz RL, Murphy GP: Management and survival of female patients with ‘minimal’ breast cancer: As observed in the long-term and short-term surveys of the American College of Surgeons. Cancer 47: 2769–2778, 1981.

    Google Scholar 

  43. McDivitt RW: Breast carcinoma. Hum Pathol 9: 3–21, 1978.

    Google Scholar 

  44. Patchefsky AS, Shaber GS, Schwartz GF, Feig SA, Nerlinger RE: The pathology of breast cancer detected by mass population screening. Cancer 40: 1659–1670, 1977.

    Google Scholar 

  45. Bland KI, Buchanan JB, Mills DL, Kuhns JG, Moore C, Spratt JS, Polk HC Jr: Analysis of breast cancer screening in women younger than 50 years. JAMA 245: 1037–1042, 1981.

    Google Scholar 

  46. Moskowitz M, Pemmaraju S, Fidler JA, Sutorius DJ, Russell P, Scheinok P, Holle J: On the diagnosis of minimal breast cancer in a screened population. Cancer 37: 2543–2552, 1976.

    Google Scholar 

  47. Bailar JC: Mammography: A contrary view. Ann Intern Med 84: 77–84, 1976.

    Google Scholar 

  48. Fisher ER, Gregorio R, Redmond C, Vellios F, Sommers SC, Fisher B: Pathological findings from the National Surgical Adjuvant Breast Project (Protocol no. 4): I. Observations concerning the multicentricity of mammary cancer. Cancer 35: 247–254, 1975.

    Google Scholar 

  49. Lagios MD: Multicentricity of breast carcinoma demonstrated by routine correlated serial subgross and radiographic examination. Cancer 40: 1726–1734, 1977.

    Google Scholar 

  50. McDivitt RW, Stewart FW, Berg JW: Tumors of the breast.In Universities Associated for Research and Education in Pathology, Inc. (eds). Fasicicle 2, Atlas of Tumor Pathology, 2nd series. Armed Forces Institute of Pathology, Washington, DC, 1968.

    Google Scholar 

  51. Robbins GF, Berg JW: Bilateral primary breast cancers: A prospective clinicopathological study. Cancer 17: 1501–1527, 1964.

    Google Scholar 

  52. Kiang DT, Kennedy BJ, Snover DC: Biological and histological characteristics of simultaneous bilateral breast cancer. Lancet 2: 1105–1108, 1980.

    Google Scholar 

  53. Cady B: Changing patterns of breast cancer. Arch Surg 104: 266–269, 1972.

    Google Scholar 

  54. Halsted WS: The results of radical operation for cure of carcinoma of the breast. Ann Surg 46: 1–19, 1907.

    Google Scholar 

  55. Fisher B, Slack N, Katrych D, Wolmark N: Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534, 1975.

    Google Scholar 

  56. Packard RA, Prosnitz LR, Bobrow SN: Selection of breast cancer patients for adjuvant chemotherapy: Another look at the prognostic importance of involved lymph nodes. JAMA 238: 1034–1036, 1977.

    Google Scholar 

  57. Fisher B, Slack NH: Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 131: 79–88, 1970.

    Google Scholar 

  58. Fisher ER, Gregorio RM, Redmond C, Kim WS, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4): III. The significance of extranodal extension of axillary metastases. Am J Clin Pathol 65: 439–444, 1976.

    Google Scholar 

  59. Huvos AG, Hutter RVP, Berg JW: Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 173: 44–46, 1971.

    Google Scholar 

  60. Fisher ER, Palekar A, Rockette H, Redmond C, Fisher B: Pathological findings from the National Surgical Adjuvant Breast Project (Protocol no. 4): V. Significance of axillary nodal micro- and macrometastases. Cancer 42: 2032–2038, 1978.

    Google Scholar 

  61. Saphir O, Amromin GD: Obscure axillary lymph-node metastases in carcinoma of the breast. Cancer 1: 238–241, 1948.

    Google Scholar 

  62. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B: Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42: 2025–2031, 1978.

    Google Scholar 

  63. Breast Cancer Study Group: Identification of breast cancer patients with high risk of early recurrence after radical mastectomy: II. Clinical and pathological correlations. Cancer 42: 2809–2826, 1978.

    Google Scholar 

  64. Ashikari R, Rosen PP, Urban JA, Senoo T: Breast cancer presenting as an axillary mass. Ann Surg 183: 415–417, 1976.

    Google Scholar 

  65. Rosen PP: Axillary lymph node metastases in patients with occult non-invasive breast carcinoma. Cancer 46: 1298–1306, 1980.

    Google Scholar 

  66. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571–573, 1889.

    Google Scholar 

  67. Colombano SP, Reese PA: The cascade theory of metastatic spread: Are there generalizing sites? Cancer 46: 2312–2314, 1980.

    Google Scholar 

  68. Fisher B, Fisher ER: The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 122: 791–798, 1966.

    Google Scholar 

  69. Zeider I, Buss JM: Experimental studies on the spread of cancer in the lymphatic system. I. Effectiveness of the lymph node as a barrier to the passage of embolic tumor cells. Cancer Res 14: 403–405, 1954.

    Google Scholar 

  70. Carr I, McGinty F: Lymphatic metastasis and its inhibition: An experimental model. J Pathol 113: 85–95, 1974.

    Google Scholar 

  71. Wood S: Mechanisms of establishment of tumor metastases.In H Ioachim (ed). Pathobiology Annual. Appleton-Century-Crofts, New York, 1971, pp 281–308.

    Google Scholar 

  72. Holleb AI, Freeman HP, Farrow JH: Cancer of male breast. NY State J Med 68: 544–556, 1968.

    Google Scholar 

  73. Scheike O: Male breast cancer: 6. Factors influencing prognosis. Br J Cancer 30: 261–271, 1974.

    Google Scholar 

  74. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne D: Male breast cancer: A clinicopathologic study of 97 cases. Ann Surg 188: 60–65, 1978.

    Google Scholar 

  75. Paone JF, Baker RR: Pathogenesis and treatment of Paget's disease of the breast. Cancer 48: 825–829, 1981.

    Google Scholar 

  76. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V: Medullary carcinoma of the breast: A clinicopathologic study with 10 year followup. Cancer 40: 1365–1385, 1977.

    Google Scholar 

  77. Brightmore TGJ, Greening WP, Hamlin I: An analysis of clinical and histopathological features in 101 cases of carcinoma of the breast in women under 35 years of age. Br J Cancer 24: 644–669, 1970.

    Google Scholar 

  78. Schwartz GF, Zeok JV: Carcinoma of the breast in young women. Am J Surg 131: 570–574, 1976.

    Google Scholar 

  79. Noyes RD, Spanos WJ, Montague ED: Breast cancer in women age 30 and under. Cancer 49: 1302–1307, 1982.

    Google Scholar 

  80. Taylor HB, Norris HJ: Well-differentiated carcinoma of the breast. Cancer 25: 687–692, 1970.

    Google Scholar 

  81. Linell F, Ljungberg O: Breast carcinoma: Progression of tubular carcinoma and a new classification. Acta Pathol Microbiol Scand [A] 88: 59–60, 1980.

    Google Scholar 

  82. Peters GN, Wolff M, Haagensen CD: Tubular carcinoma of the breast: Clinical pathologic correlations based on 100 cases. Ann Surg 193: 138–149, 1981.

    Google Scholar 

  83. Carstens PHB, Huvos AG, Foote FW, Ashikari R: Tubular carcinoma of the breast: A clinicopathologic study of 35 cases. Am J Clin Pathol 58: 231–238, 1972.

    Google Scholar 

  84. Foulds L: The experimental study of tumor progression: A review. Cancer Res 14: 327–339, 1954.

    Google Scholar 

  85. Martinez V, Azzopardi JG: Invasive lobular carcinoma of the breast: Incidence and variants. Histopathology 3: 467–488, 1979.

    Google Scholar 

  86. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast. Histopathology 6: 149–161, 1982.

    Google Scholar 

  87. Fechner RE: Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 6: 373–378, 1975.

    Google Scholar 

  88. Morrison AS, Black MM, Lowe CR, Macmahon B, Yuasa S: Some international differences in histology and survival in breast cancer. Int J Cancer 11: 261–267, 1973.

    Google Scholar 

  89. Rosen PP, Ashikari R, Thaler H, Ishikawa S, Hirota T, Abe O, Yamamoto H, Beattie EJ, Urban JA, Mike V: A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA. Cancer 39: 429–434, 1977.

    Google Scholar 

  90. Stewart FW:In Tumors of the Breast. Armed Forces Institute of Pathology, Washington, DC, 1950, pp 1–114.

    Google Scholar 

  91. MacCarty WC: Factors which influence longevity in cancer: A study of 293 cases. Ann Surg 76: 9–13, 1922.

    Google Scholar 

  92. Greenough RB: Varying degrees of malignancy in cancer of the breast. J Cancer Res 9: 453–463, 1925.

    Google Scholar 

  93. Patey DH, Scarff RW: The position of histology in the prognosis of carcinoma of the breast. Lancet 1: 801–804, 1928.

    Google Scholar 

  94. Haagensen CD: The bases for the histologic grading of carcinoma of the breast. Am J Cancer 19: 285–327, 1933.

    Google Scholar 

  95. Bloom HJG: Prognosis in carcinoma of the breast. Br J Cancer 4: 259–288, 1950.

    Google Scholar 

  96. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377, 1957.

    Google Scholar 

  97. Champion HR, Wallace IWJ: Breast cancer grading. Br J Cancer 25: 441–448, 1971.

    Google Scholar 

  98. Champion HR, Wallace IWJ, Prescott RJ: Histology in breast cancer prognosis. Br J Cancer 26: 129–138, 1972.

    Google Scholar 

  99. Fisher ER, Redmond C, Fisher B: Histologic grading of breast cancer.In SC Sommers and PP Rosen (eds). Pathology Annual 1980, Part I. Appleton-Century-Crofts, New York, 1980, pp 239–251.

    Google Scholar 

  100. Alderson MR, Hamlin I, Staunton MD: The relative significance of prognostic factors in breast carcinoma. Br J Cancer 25: 646–656, 1971.

    Google Scholar 

  101. Hartveit F: Prognostic typing in breast cancer. Br Med J 4: 253–257, 1971.

    Google Scholar 

  102. Cutler SJ, Black MM, Friedell GH, Vidone R, Goldenberg IS: Prognostic factors in cancer of the female breast: II. Reproducibility of histopathologic classification. Cancer 19: 75, 1966.

    Google Scholar 

  103. Delides GS, Garas G, Georgouli G, Jiortziotis D, Lecca J, Liva T, Elemenoglou J: Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med 106: 126–128, 1982.

    Google Scholar 

  104. Rich MA, Brennan MJ: The breast cancer prognostic program: A study of the metastatic process.In MJ Brennan, CM McGrath, and MA Rich (eds). Breast Cancer: New Concepts in Etiology and Control. Academic Press, New York, 1980, pp 29–51.

    Google Scholar 

  105. Underwood JCE: A morphometric analysis of human breast carcinoma. Br J Cancer 26: 234–237, 1972.

    Google Scholar 

  106. Sharkey FE, Pavlak RJ: Quantitative morphometric analysis of differentiation vs. prognosis in human breast cancer (Abstract). Proc Am Assoc Cancer Res 22: 182, 1981.

    Google Scholar 

  107. Stenkvist B, Bengtsson E, Eriksson O, Jarkans T, Nordin B: A morphometric expression of differentiation in fineneedle biopsies of breast cancer. Cytometry 1: 292–295, 1981.

    Google Scholar 

  108. Baak JPA, Kurver PHJ, Desnoo-Niewlaat AJE, Degraef S, Makkink B, Boon ME: Prognostic indicators in breast cancer — morphometric methods. Histopathology 6: 327–339, 1982.

    Google Scholar 

  109. Willis RA: Epithelial tumors of the breast.In Pathology of Tumors, 4th ed. Appleton-Century-Crofts, New York, 1967, pp 208–256.

    Google Scholar 

  110. Lane N, Goskel H, Salerno RA, Haagensen CD: Clinicopathologic analysis of the surgical curability of breast cancers: A minimum ten-year study of a personal series. Ann Surg 153: 483–498, 1961.

    Google Scholar 

  111. Silverberg SG, Chitale AR, Livitt SH: Prognostic significance of tumor margins in mammary carcinoma. Arch Surg 102: 450–454, 1971.

    Google Scholar 

  112. Nime FA, Rosen PP, Thaler HT, Ashikari R, Urban J: Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol 1: 25–30, 1977.

    Google Scholar 

  113. Kister SJ, Sommers SC, Haagensen CD, Cooley E: Reevaluation of blood vessel invasion as a prognostic factor in carcinoma of the breast. Cancer 19: 1213–1216, 1966.

    Google Scholar 

  114. Lucas FV, Perez-Mesa C: Inflammatory carcinoma of the breast. Cancer 41: 1595–1605, 1978.

    Google Scholar 

  115. Gilchrist KW, Gould VE, Hirschl S, Imbriglia JE, Patchefsky AS, Penner DW, Pickren J, Schwartz IS, Wheeler JE, Barnes JM, Mansour EG: Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol 13: 170–172, 1982.

    Google Scholar 

  116. Fisher ER, Palekar AS, Gregorio RM, Redmond C, Fisher B: Pathological findings from the National Surgical Adjuvant Breast Project (Protocol no. 4): IV. Significance of tumor necrosis. Hum Pathol 9: 523–530, 1978.

    Google Scholar 

  117. Fournier DV, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V: Growth rate of 147 mammary carcinomas. Cancer 45: 2198–2207, 1980.

    Google Scholar 

  118. Spratt JS, Heuser L, Kuhns JG, Reiman HM, Buchanan JB, Polk HC Jr, Sandoz J: Association between the actual doubling times of primary breast cancer with histopathologic characteristics and Wolfe's parenchymal mammographic patterns. Cancer 47: 2265–2268, 1981.

    Google Scholar 

  119. Black MM, Speer FD, Opler SR: Structural representations of tumor-host relationships in mammary carcinoma; biologic and prognostic significance. Am J Clin Pathol 26: 250–265, 1956.

    Google Scholar 

  120. Slack NH, Blumenson LE, Bross IDJ: Therapeutic implications from a mathematical model characterizing the course of breast cancer. Cancer 24: 960–971, 1969.

    Google Scholar 

  121. Silvestrini R, Sanfilippo O, Tedesco G: Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer 34: 1252–1258, 1974.

    Google Scholar 

  122. Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48: 974–979, 1981.

    Google Scholar 

  123. Olszewski W, Darzynkiewicz Z, Rosen PP, Schwartz MK, Melamed MR: Flow cytometry of breast carcinoma: I. Relation of DNA ploidy level to histology and estrogen receptor. Cancer 48: 980–984, 1981.

    Google Scholar 

  124. Tubiana M, Pejovic MJ, Renaud A, Contesso G, Chavaudra N, Goianni J, Malaise EP: Kinetic parameters and the course of the disease in breast cancer. Cancer 47: 937–943, 1981.

    Google Scholar 

  125. Schiffer LM, Braunschweiger PG, Stragand JJ, Poulakos L: The cell kinetics of human mammary cancers. Cancer 43: 1707–1719, 1979.

    Google Scholar 

  126. Straus MJ, Moran RE: The cell cycle kinetics of human breast cancer. Cancer 46: 2634–2639, 1980.

    Google Scholar 

  127. Charlson ME, Feinstein AR: A new clinical index of growth rate in the staging of breast cancer. Am J Med 69: 527–536, 1980.

    Google Scholar 

  128. Meyer JS, Hixon B: Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res 39: 4042–4047, 1979.

    Google Scholar 

  129. Waalkes TP, Tormey DC: Biologic markers and breast cancer. Semin Oncol 5: 434–444, 1978.

    Google Scholar 

  130. Gupta RK, Schuster R: Isoantigens A, B and H in benign and malignant lesions of the breast. Am J Pathol 72: 253–257, 1973.

    Google Scholar 

  131. Strauchen JA, Bergman SM, Hanson TAS: Expression of A and B tissue isoantigens in benign and malignant lesions of the breast. Cancer 45: 2149–2155, 1980.

    Google Scholar 

  132. Kovarik S, Davidsohn I, Stejskal R: ABO antigens in cancer: Detection with the mixed cell agglutination reaction. Arch Pathol 86: 12–21, 1969.

    Google Scholar 

  133. Kay HEM: A and B antigens of normal and malignant cells. Br J Cancer 11: 409–414, 1957.

    Google Scholar 

  134. Davidsohn I: Early immunologic diagnosis and prognosis of carcinoma. Am J Clin Pathol 57: 715–730, 1972.

    Google Scholar 

  135. Springer GF, Desai PR, Banatwala I: Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. JNCI 54: 335–339, 1975.

    Google Scholar 

  136. Newman RA, Klein PJ, Uhlenbruck G, Citoler P, Karduck D: The presence and significance of the Thomsen-Friedenreich antigen in breast cancer. I. Serological studies. J Cancer Res Clin Oncol 93: 181–188, 1979.

    Google Scholar 

  137. Howard DR, Batsakis JG: Cytostructural localization of a tumor-associated antigen. Science 210: 201–203, 1980.

    Google Scholar 

  138. Stoward PJ, Spicer SS, Miller RL: Histochemical reactivity of peanut lectin-horseradish peroxidase conjugate. J Histochem Cytochem 28: 979–990, 1980.

    Google Scholar 

  139. Franklin WA: Differences in binding among lectins to lesions of the breast. Lab Invest 42: 26A, 1982.

  140. Furmanski P, Kirkland WL, Gargala T, Rich MA, and the Breast Cancer Prognostic Study Clinical Associates: Prognostic value of concanavalin A reactivity of primary human breast cancer cells. Cancer Res 41: 4087–4092, 1981.

    Google Scholar 

  141. Klein PJ, Newman RA, Muller P, Uhlenbruck G, Citoler P, Schaefer HE, Lennartz KJ, Fischer R: The presence and significance of Thomsen-Friedenreich antigen in mammary gland. J Cancer Res Clin Oncol 93: 205–214, 1979.

    Google Scholar 

  142. Newman RA, Klein PJ, Rudland PS: Binding of peanut lectin to breast epithelium, human carcinomas, and a cultured rat mammary stem cell: Use of the lectin as a marker of mammary differentiation. JNCI 63: 1339–1346, 1979.

    Google Scholar 

  143. Hollinshead AC, Jaffurs WT, Alpert LK, Harris JE, Herberman RB: Isolation and identification of soluble skin-reactive membrane antigens of malignant and normal human breast cells. Cancer Res 34: 2961–2968, 1974.

    Google Scholar 

  144. Ceriani RL, Thompson K, Peterson JA, Abraham S: Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci USA 72: 582–586, 1977.

    Google Scholar 

  145. Heyderman E, Steele K, Ormerod MG: A new antigen on the epithelial membrane: Its immunoperoxidase localization in normal and neoplastic tissue. J Clin Pathol 32: 35–39, 1979.

    Google Scholar 

  146. Arklie J, Taylor-Papadimitriou J, Bodmer W, Egan M, Millis R: Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer 28: 23–29, 1981.

    Google Scholar 

  147. Foster CS, Dinsdale EA, Edwards PAW, Neville AM: Monoclonal antibodies to the human mammary gland: II. Distribution of determinants in breast carcinomas. Virchows Arch [Pathol Anat] 394: 295–305, 1982.

    Google Scholar 

  148. Egan ML, Henson DE: Monoclonal antibodies and breast cancer. JNCI 68: 338–340, 1982.

    Google Scholar 

  149. Tourville DR, Adler RH, Bienenstock J, Tomasi TB: The human secretory immunoglobulin system: Immunohistological localization of IGA, secretory ‘piece’, and lactoferrin in normal human tissues. J Exp Med 129: 411–429, 1969.

    Google Scholar 

  150. Harris JP, South MA: Secretory component: A glandular epithelial cell marker. Am J Pathol 105: 47–53, 1981.

    Google Scholar 

  151. Syre G, Sehn M: Intracellular storage of IGA and secretory component in carcinomas of the female breast. Virchows Arch [Pathol Anat] 393: 315–320, 1981.

    Google Scholar 

  152. Walker RA: Differentiation of human breast carcinomas: An immunohistological study of appropriate and inappropriate protein production. J Pathol 135: 87–95, 1981.

    Google Scholar 

  153. Hsu SM, Raine L, Nayak RN: Medullary carcinoma of the breast: An immunohistological study of its lymphoid structure. Cancer 48: 1368–1376, 1981.

    Google Scholar 

  154. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. JNCI 64: 1061–1070, 1980.

    Google Scholar 

  155. Recklies AD, Tiltman KJ, Stoker TAM, Poole AR: Secretion of proteinases from malignant and nonmalignant human breast tissue. Cancer Res 40: 550–556, 1980.

    Google Scholar 

  156. Albrechtsen R, Nielsen M, Wewer U, Engvall E, Ruoslahti E: Basement membrane changes in breast cancer detected by immunohistochemical staining for laminin. Cancer Res 41: 5076–5081, 1981.

    Google Scholar 

  157. Weiss MA, Michael JG, Pesce AJ, Dipersio L: Heterogeneity of beta-2-microglobulin in human breast carcinoma. Lab Invest 45: 46–57, 1981.

    Google Scholar 

  158. Stampfer MR, Vlodavsky I, Smith HS, Ford R, Becker FF, Riggs J: Fibronectin production by human mammary cells. JNCI 67: 253–261, 1981.

    Google Scholar 

  159. Taylor-Papadimitriou J, Burchell J, Hurst J: Production of fibronectin by normal and malignant human mammary epithelial cells. Cancer Res 41: 2491–2500, 1981.

    Google Scholar 

  160. Cox C, Silva J, Haagensen D, McCarty K Sr, Fetter B, Dilley W, McCarty K Jr, Wells S: Biochemical correlates of morphologic differentiation in human breast cancer (Abstract). Proc Am Assoc Cancer Res 22: 185, 1981.

    Google Scholar 

  161. Deshpande N, Mitchell I, Millis R: Tumour enzymes and prognosis in human breast cancer. Eur J Cancer 17: 443–448, 1981.

    Google Scholar 

  162. Savlov ED, Hilf R, Gibson SL, Feldstein M: Low tissue enzyme activity seen in breast cancers of patients who fail adjuvant chemotherapy. Cancer 47: 2214–2217, 1981.

    Google Scholar 

  163. Monaco ME, Bronzert BA, Tormey DC, Waalkes P, Lippman ME: Casein production by human breast cancer. Cancer Res 37: 749–754, 1977.

    Google Scholar 

  164. Bahu RM, Mangkornkanok-Mark M, Albertson D, Fors E, Molteni A, Battifora H: Detection of alpha-lactalbumin in breast lesions and relationship to estrogen receptors and serum protein. Cancer 46: 1775–1780, 1980.

    Google Scholar 

  165. Schultz GS, Ebner KE: Alpha-lactalbumin levels in human mammary tumors, sera, and mammary culture lines. Cancer Res 37: 4489–4492, 1977.

    Google Scholar 

  166. Kuhajda FP, Mendelsohn G: Carcinoembryonic antigen and alpha-lactalbumin in breast carcinoma: An immunohistochemical study. Lab Invest 46: 46A, 1982.

  167. Horne CHW, Reid IN, Milne GD: Prognostic significance of inappropriate production of pregnancy proteins by breast cancers. Lancet 2: 279–282, 1976.

    Google Scholar 

  168. Walker RA: Significance of alpha-subunit HCG demonstrated in breast carcinomas by the immunoperoxidase technique. J Clin Pathol 31: 245–249, 1978.

    Google Scholar 

  169. Fortt RW, Gibbs AR, Williams D, Hansen J, Williams I: The identification of ‘casein’ in human breast cancer. Histopathology 3: 395–406, 1979.

    Google Scholar 

  170. Bussolati G, Pich A, Alfani V: Immunofluorescence detection of casein in human mammary dysplastic and neoplastic tissues. Virchows Arch [Pathol Anat] 365: 15–21, 1975.

    Google Scholar 

  171. Walker RA: The demonstration of alpha-lactalbumin in human breast carcinomas. J Path 129: 37–42, 1979.

    Google Scholar 

  172. Tormey DC, Waalkes TP, Ahmann D, Gehrke CW, Zumwatt RW, Snyder J, Hansen H: Biological markers in breast carcinoma: I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. Cancer 35: 1095–1100, 1975.

    Google Scholar 

  173. Wilkinson EJ, Hause LL, Sasse EA, Pattillo RA, Milbrath JR, Lewis JD: Carcinoembryonic antigen and L-fucose in malignant and benign mammary disease. Am J Clin Pathol 73: 669–675, 1980.

    Google Scholar 

  174. Shousha S, Lyssiotis T: Correlation of carcinoembryonic antigen in tissue sections with spread of mammary carcinoma. Histopathology 2: 433–447, 1978.

    Google Scholar 

  175. Walker RA: Demonstration of carcinoembryonic antigen in human breast carcinomas by the immunoperoxidase technique. J Clin Pathol 33: 356–360, 1980.

    Google Scholar 

  176. Faulk WP, Hsi B-L, Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2: 390–392, 1980.

    Google Scholar 

  177. Yu GSM, Kadish AS, Johnson AB, Marcus DM: Breast carcinoma-associated antigen: An immunocytochemical study. Am J Clin Pathol 74: 453–457, 1980.

    Google Scholar 

  178. Colcher D, Hand PH, Nuti M, Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78: 3199–3203, 1981.

    Google Scholar 

  179. Kuo TT, Rosai J, Tillack TW: Immunological studies of membrane glycoproteins isolated from human breast carcinomas. Int J Cancer 12: 532–542, 1973.

    Google Scholar 

  180. Kamiyama M, Hashim GA, Kyriakidis G, Fitzpatrick HF: A tumor-associated antigen isolated from human breast adenocarcinoma. Clin Immunol Immunopathol 16: 151–165, 1980.

    Google Scholar 

  181. Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HMD, Powles TJ, Ford HT, Gazet J-C, Neville AM: Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigens. Br J Cancer 44: 85–90, 1981.

    Google Scholar 

  182. Farr AG, Nakane PK: Immunohistochemistry with enzyme labeled antibodies: A brief review. J Immunol Methods 47: 129–144, 1981.

    Google Scholar 

  183. Pinkus GS: Diagnostic immunocytochemistry of paraffinembedded tissues. Hum Pathol 13: 411–415, 1982.

    Google Scholar 

  184. Lippman ME, Allegra JC: Estrogen receptor and endocrine therapy of breast cancer. N Engl J Med 299: 930–933, 1978.

    Google Scholar 

  185. Blamey RW, Bishop HM, Blake JRS, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship between primary breast tumor receptor status and patient survival. Cancer 46: 2765–2769, 1980.

    Google Scholar 

  186. Furmanski P, Saunders DE, Brooks SC, Rich MA, and the Breast Cancer Prognostic Study Clinical and Pathology Associates: The prognostic value of estrogen receptor determinations in patients with primary breast cancer: An update. Cancer 46: 2794–2796, 1980.

    Google Scholar 

  187. Hilf R, Feldstein ML, Gibson SL, Savlov ED: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45: 1993–2000, 1980.

    Google Scholar 

  188. Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669–4671, 1977.

    Google Scholar 

  189. Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38: 4292–4295, 1978.

    Google Scholar 

  190. Godolphin W, Elwood JM, Spinelli JJ: Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: A study of 583 patients. Int J Cancer 28: 677–683, 1981.

    Google Scholar 

  191. Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981.

    Google Scholar 

  192. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang K-P, Romsdahl MM, Martin R: Estrogen receptor: A prognostic factor in breast cancer. Cancer 47: 554–560, 1981.

    Google Scholar 

  193. Westerberg H, Gustafson SA, Nordenskjold B, Silfversward C, Wallgren A: Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer 26: 429–433, 1980.

    Google Scholar 

  194. Fletcher WS, Leung BS, Davenport CE: The prognostic significance of estrogen receptors in human breast cancer. Am J Surg 135: 372–374, 1978.

    Google Scholar 

  195. Delarue JC, May-Levin F, Mouriesse H, Contesso G, Sancho-Garnier H: Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer 44: 911–916, 1981.

    Google Scholar 

  196. McCarty KS Jr, Barton TS, Fetter BF, Woodard BH, Mossler JA, Reeves W, Daly J, Wilkinson WE, McCarty KS Sr: Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer 46: 2851–2858, 1980.

    Google Scholar 

  197. Singhakowinta A, Saunders DE, Brooks SC, Samal B, Vaitkevicius VK: Clinical application of estrogen receptor in breast cancer. Cancer 46: 2932–2938, 1980.

    Google Scholar 

  198. Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17: 449–453, 1981.

    Google Scholar 

  199. King RJB: Clinical relevance of steroid-receptor measurements in tumours. Cancer Treat Rev 2: 273–293, 1975.

    Google Scholar 

  200. Rosen PP, Menendez-Botet CJ, Urban JA, Fracchia A, Schwartz MK: Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 39: 2194–2200, 1977.

    Google Scholar 

  201. Allegra JC, Barlock A, Huff KK, Lippman ME: Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 45: 792–794, 1980.

    Google Scholar 

  202. Kiang DT, Kennedy BJ: Factors affecting estrogen receptors in breast cancer. Cancer 40: 1571–1576, 1977.

    Google Scholar 

  203. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330–1334, 1978.

    Google Scholar 

  204. Janssens JP, Wittevrongel C, Van Dam J, Goddeeris P, Lauwerijns JM, De Loecker W: Effects of ionizing irradiation on the estradiol and progesterone receptors in rat mammary tumors. Cancer Res 41: 703–707, 1981.

    Google Scholar 

  205. Janssens JP, Bonte J, Drochmans A, Mulier J, Rutten J, Wittevrongel C, De Loecker W: Effect of presurgical radiotherapy on the steroid receptor concentrations in primary breast carcinoma. Eur J Cancer 17: 659–664, 1981.

    Google Scholar 

  206. Chamness GC, McGuire WL: Questions about histochemical methods for steroid receptors. Arch Pathol Lab Med 106: 53–54, 1982.

    Google Scholar 

  207. McCarty KS Jr, Woodard BH, Nichols DE, Wilkinson W, McCarty KS Sr: Comparison of biochemical and histochemical techniques for estrogen receptor analyses in mammary carcinoma. Cancer 46: 2842–2845, 1980.

    Google Scholar 

  208. Chamness GC, Mercer WD, McGuire WL: Are histochemical methods for estrogen receptor valid? J Histochem Cytochem 28: 792–798, 1980.

    Google Scholar 

  209. Nadji M, Morales AR, Greene GL, Jensen EV: Immunohistologic demonstration of estrogen receptor in breast carcinoma using monoclonal antibodies. Lab Invest 46: 60A, 1982.

  210. Tamura H, Raam S, Nemeth E, Cohen J: Immunohistochemical detection of estrogen receptors in human breast carcinomas using antireceptor antibodies: Its application to cytologic material (Abstract). Lab Invest 46: 82A, 1982.

  211. Horwitz KB, McGuire WL, Pearson OH, Segaloff A: Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 189: 726–727, 1975.

    Google Scholar 

  212. McGuire WL: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428–433, 1978.

    Google Scholar 

  213. Sarrif AM, Durant JR: Evidence that estrogen-receptornegative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor. Cancer 48: 1215–1220, 1981.

    Google Scholar 

  214. Nomura A, Yamagata Y, Takenaka K, Tashiro H: Steroid hormone receptors and clinical usefulness in human breast cancer. Cancer 46: 2880–2883, 1980.

    Google Scholar 

  215. Pichon MF, Pallud C, Brunet M, Milgrom E: Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 40: 3357–3360, 1980.

    Google Scholar 

  216. Bertuzzi A, Vezzoni P, Ronchi E: Prognostic importance of progesterone receptors (PR) alone or in combination with estrogen receptors (ER) in node-negative (N−) breast carcinoma (Abstract). Proc Am Soc Clin Oncol 22: 447, 1981.

    Google Scholar 

  217. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, Urban JA, Mike V, Fracchia A, Schwartz MK: Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res 35: 3187–3194, 1975.

    Google Scholar 

  218. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B, and Collaborating NSABP Investigators: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45: 349–353, 1980.

    Google Scholar 

  219. Millis RR: Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46: 2869–2871, 1980.

    Google Scholar 

  220. Kern WH: Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast. Surg Gynecol Obstet 148: 240–242, 1979.

    Google Scholar 

  221. Lee SH: Cancer cell estrogen receptor of human mammary carcinoma. Cancer 44: 1–12, 1979.

    Google Scholar 

  222. Parl FF, Wagner RK: The histopathological evaluation of human breast cancers in correlation with estrogen receptor values. Cancer 46: 362–367, 1980.

    Google Scholar 

  223. Antoniades K, Spector H: Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer. Am J Clin Pathol 71: 497–503, 1979.

    Google Scholar 

  224. Masters JRW, Sangster K, Hawkins RA, Shivas AA: Elastosis and estrogen receptors in human breast cancer. Br J Cancer 33: 342–343, 1976.

    Google Scholar 

  225. Shivas AA, Douglas JG: The prognostic significance of elastosis in breast carcinoma. J R Coll Surg Edinb 17: 315–320, 1972.

    Google Scholar 

  226. Meyer JS, Rao BR, Stevens SC, White WL: Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40: 2290–2298, 1977.

    Google Scholar 

  227. Silvestrini R, Daidone MG, Difronzo G: Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44: 665–670, 1979.

    Google Scholar 

  228. Lesser ML, Rosen PP, Senie RT, Duthie K, Menendez-Botet C, Schwartz MK: Estrogen and progesterone receptors in breast carcinoma: Correlations with epidemiology and pathology. Cancer 48: 299–309, 1981.

    Google Scholar 

  229. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 13: 1–27, 1970.

    Google Scholar 

  230. Prehn RT, Lappe MA: An immunostimulation theory of tumor development. Transplant Rev 7: 26–54, 1971.

    Google Scholar 

  231. Moore OS, Foote FW Jr: The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 2: 635–642, 1949.

    Google Scholar 

  232. Hamlin I: Possible host resistance in carcinoma of the breast: A histological study. Br J Cancer 22: 383–401, 1968.

    Google Scholar 

  233. Berg JW: Inflammation and prognosis in breast cancer — a search for host resistance. Cancer 12: 714–720, 1959.

    Google Scholar 

  234. Black MM, Barclay THC, Hankey BF: Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer 36: 2048–2055, 1975.

    Google Scholar 

  235. Mortensen RF, and the Breast Cancer Prognostic Study Clinical Associates: Prognostic value and functional activities of lymphoid cells infiltrating human breast tumors (Abstract). Proc Am Assoc Cancer Res 21: 227, 1980.

    Google Scholar 

  236. Elston CW, Gresham GA, Rao GS, Zebro T, Haybittle JL, Houghton J, Kearney G: The cancer research campaign (King's/Cambridge) trial for early breast cancer: Clinico-pathological aspects. Br J Cancer 45: 655–669, 1982.

    Google Scholar 

  237. Lauder I, Aherne W, Stewart J, Sainsbury R: Macrophage infiltration of breast tumors: A prospective study. J Clin Path 30: 563–568, 1977.

    Google Scholar 

  238. Husby G, Hoagland PM, Strickland RG, Williams RC: Tissue T and B cell infiltration of primary and metastatic cancer. J Clin Invest 57: 1471–1482, 1976.

    Google Scholar 

  239. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K: Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti-human T- and B-cell sera. Cancer 49: 1456–1464, 1982.

    Google Scholar 

  240. Vose BM, Moore M: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer 24: 579–585, 1979.

    Google Scholar 

  241. Eremin O, Coombs RRA, Ashby J: Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer 44: 166–176, 1981.

    Google Scholar 

  242. Renk CM, Gupta RK, Morton DL: Immunosuppressive factors from human breast carcinoma cell lines that affect initiation of lymphocyte proliferation. Cancer Immunol Immunother 9: 55–62, 1980.

    Google Scholar 

  243. Black MM, Speer FD: Sinus histiocytosis of lymph nodes in cancer. Surg Gynecol Obstet 106: 163–175, 1958.

    Google Scholar 

  244. Hunter RL, Ferguson DJ, Coppleson LW: Survival with mammary cancer related to the interaction of germinal center hyperplasia and sinus histiocytosis in axillary and internal mammary lymph nodes. Cancer 36: 528–539, 1975.

    Google Scholar 

  245. Dire JJ, Lane N: The relation of sinus histiocytosis in axillary lymph nodes to surgical curability of carcinoma of the breast. Am J Clin Pathol 40: 508–515, 1963.

    Google Scholar 

  246. Tsakraklides V, Olson P, Kersey JH, Good RA: Prognostic significance of the regional lymph node histology in cancer of the breast. Cancer 34: 1259–1267, 1974.

    Google Scholar 

  247. Vandevelde JH, Meyer CJLM, Cornelisse CJ, Vandervelde EA, Vanputten LM, Zwaveling A: A morphometrical analysis of lymph node responses to tumors of different immunogenicity. Cancer Res 38: 661–667, 1978.

    Google Scholar 

  248. Kiricuta I, Todorutiu C, Mulea R, Risca R: Axillary lymph-node and breast carcinoma interrelations in organ culture. Cancer 42: 2710–2715, 1978.

    Google Scholar 

  249. Check IJ, Cobb M, Hunter RL: The relationship between cytotoxicity and prognostically significant histologic changes in lymph nodes from patients with cancer of the breast. Am J Pathol 98: 325–338, 1980.

    Google Scholar 

  250. Gewant WC, Chasin L, Tilson MD, Rutledge C, Goldenberg IS: Lymph node-breast carcinoma interrelations in tissue culture. Surg Gynecol Obstet 133: 959–962, 1971.

    Google Scholar 

  251. Heidenreich W, Jagla K, Schussler J, Borner P, Dehnhard F, Kalden JR, Leibold W, Peter HH, Deicher H: Spontaneous cell-mediated cytotoxicity (SCMC) and antibodydependent cellular cytotoxicity (ADCC) in peripheral blood and draining lymph nodes of patients with mammary carcinoma. Cancer Immunol Immunother 7: 65–69, 1979.

    Google Scholar 

  252. Cannon GB, Bonnard GD, Djeu J, West WH, Herberman RB: Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells. Int J Cancer 19: 487–497, 1977.

    Google Scholar 

  253. Black MM, Leis H, Shore B, Zachrau RE: Cellular hypersensitivity to breast cancer: Assessment by a leukocyte migration procedure. Cancer 33: 952–958, 1974.

    Google Scholar 

  254. Hager JC, Rudczynski AB, Mortensen RF, Heppner GH, Furmanski P, Rich MA and the Breast Cancer Prognostic Study Clinical and Pathology Associates: Is tumor-associated immunologic reactivity in breast cancer patients prognostically significant? (Abstract). Proc Am Assoc Cancer Res 22: 145, 1981.

    Google Scholar 

  255. Hudson MJK, Humphrey LJ, Mantz FA, Morse PA: Correlation of circulating serum antibody to the histologic findings in breast cancer. Am J Surg 128: 756–762, 1974.

    Google Scholar 

  256. Krown SE, Pinsky CM, Wanebo HJ, Braun DW, Wong PP, Oettgen HF: Immunologic reactivity and prognosis in breast cancer. Cancer 46: 1746–1752, 1980.

    Google Scholar 

  257. Wanebo HJ, Rosen PP, Thaler T, Urban JA, Oettgen HF: Immunobiology of operable breast cancer: An assessment of biologic risk by immunoparameters. Ann Surg 184: 258–266, 1976.

    Google Scholar 

  258. Adler A, Stein JA, Ben-Efraim S: Immunocompetence, immunosuppression, and human breast cancer: II. Further evidence of initial immune impairment by integrated assessment — effect of nodal involvement (N) and of primary tumor size (T). Cancer 45: 2061–2073, 1980.

    Google Scholar 

  259. Herberman RB: Assessment of cellular immune response to cancer of the breast. Ann Clin Lab Sci 9: 467–473, 1979.

    Google Scholar 

  260. Wallgren A, Silfversward C, Eklund G: Prognostic factors in mammary carcinoma. Acta Radiol Ther Phys Biol 15: 1–16, 1976.

    Google Scholar 

  261. Freedman LS, Edwards DN, McConnell EM, Downham DY: Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer 40: 44–55, 1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Specialized Cancer Research Center, College of Medicine, The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA

    Francis E. Sharkey M.D.

Authors
  1. Francis E. Sharkey M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharkey, F.E. Biological meaning of stage and grade in human breast cancer: Review and hypothesis. Breast Cancer Res Tr 2, 299–322 (1982). https://doi.org/10.1007/BF01805872

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01805872

Keywords

Search

Navigation